Skip to main content
. 2020 Sep 28;38(34):4042–4054. doi: 10.1200/JCO.20.00948

FIG 5.

FIG 5.

Multivariable analysis of progression-free survival (PFS) according to (A) genomic complexity (GC) status and (B) driver mutation burden (number of recurrently mutated genes with mutations). Covariates were IGHV status, Rai stage at baseline, TP53 mutation status and/or del(17p) by array comparative genomic hybridization, fludarabine resistance status, and maximum nodal size > 10 cm. BR, bendamustine plus rituximab; HR, hazard ratio; VenR, venetoclax plus rituximab.